Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar

Blood

Volumn 125, Issue 12, 2015, Pages 1976-1985

  Aisiku, Omozuanvbo ^a   Peters, Christian G ^a   De Ceunynck, Karen ^a   Ghosh, Chandra C ^b   Dilks, James R ^a   Fustolo Gunnink, Susanna F ^a   Huang, Mingdong ^a   Dockendorff, Chris ^c   Parikh, Samir M ^b   Flaumenhaft, Robert ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Marquette University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; G PROTEIN COUPLED RECEPTOR; PARMODULIN; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VORAPAXAR; ANTITHROMBOCYTIC AGENT; LACTONE; LIGAND; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR 1; PYRIDINE DERIVATIVE; SMALL INTERFERING RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; BINDING SITE; BLOOD CLOTTING; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; CYTOPLASM; DRUG EFFECTS; EXOCYTOSIS; INFLAMMATION; INJURIES; METABOLISM; THROMBOSIS; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM;

ANIMALS; APOPTOSIS; BINDING SITES; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOPLASM; ENDOTHELIUM, VASCULAR; EXOCYTOSIS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; LACTONES; LIGANDS; PLATELET AGGREGATION INHIBITORS; PROTEIN C; PYRIDINES; RECEPTOR, PAR-1; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 84925359034     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-599910     Document Type: Article

References (45)

1. Zhang C, Srinivasan Y, Arlow DH, et al. High-resolution crystal structure of human protease-activated receptor 1. Nature. 2012;492(7429):387-392.
2. Tressel SL, Kaneider NC, Kasuda S, et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med. 2011;3(7):370-384.
3. Kataoka H, Hamilton JR, McKemy DD, et al. Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood. 2003;102(9):3224-3231.
4. Knezevic N, Tauseef M, Thennes T, Mehta D. The G protein betagamma subunit mediates reannealing of adherens junctions to reverse endothelial permeability increase by thrombin. J Exp Med. 2009;206(12):2761-2777.
5. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296(5574):1880-1882.
6. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007;109(8):3161-3172.
7. Mosnier LO, Sinha RK, Burnier L, Bouwens EA, Griffin JH. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood. 2012;120(26):5237-5246.
8. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987;79(3):918-925.
9. Bae J-S, Yang L, Manithody C, Rezaie AR. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood. 2007;110(12):3909-3916.
10. Bae J-S, Rezaie AR. Thrombin upregulates the angiopoietin-Tie2 Axis: endothelial protein C receptor occupancy prevents the thrombin mobilization of angiopoietin 2 and P-selectin from Weibel-Palade bodies. J Thromb Haemost. 2010;8(5):1107-1115.
11. Bae J-S, Rezaie AR. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thromb Haemost. 2008;100(1):101-109.
12. Bernatowicz MS, Klimas CE, Hartl KS, Peluso M, Allegretto NJ, Seiler SM. Development of potent thrombin receptor antagonist peptides. J Med Chem. 1996;39(25):4879-4887.
13. Andrade-Gordon P, Maryanoff BE, Derian CK, et al. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci USA. 1999;96(22):12257-12262.
14. Ahn HS, Foster C, Boykow G, Stamford A, Manna M, Graziano M. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol. 2000;60(10):1425-1434.
15. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008;51(11):3061-3064.
16. Matsuoka T, Kogushi M, Kawata T, et al. Inhibitory effect of E5555, an orally active thrombin receptor antagonist, on intimal hyperplasia following balloon injury. J Am Coll Cardiol. 2004;43:68A.
17. Tricoci P, Huang Z, Held C, et al TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366(1):20-33.
18. Morrow DA, Braunwald E, Bonaca MP, et al; TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404-1413.
19. Lee M, Saver JL, Hong K-S, Wu H-C, Ovbiagele B. Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists. Stroke. 2012;43(12):3189-3195.
20. Capodanno D, Bhatt DL, Goto S, et al. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. J Thromb Haemost. 2012;10(10):2006-2015.
21. May LT, Leach K, Sexton PM, Christopoulos A. Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol. 2007;47:1-51.
22. Dowal L, Sim DS, Dilks JR, et al. Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1. Proc Natl Acad Sci USA. 2011;108(7):2951-2956.
23. Vanhoorelbeke K, Cauwenberghs N, Vauterin S, Schlammadinger A, Mazurier C, Deckmyn H. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost. 2000;83(1):107-113.
24. Garcia JG, Liu F, Verin AD, et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest. 2001;108(5):689-701.
25. Dockendorff C, Aisiku O, Verplank L, et al. Discovery of 1,3-Diaminobenzenes as Selective Inhibitors of Platelet Activation at the PAR1 Receptor. ACS Med Chem Lett. 2012;3(3):232-237.
26. VerPlank L, et al. Chemical genetic analysis of platelet granule secretion-probe 2. Probe Reports from NIH Mol Libr Progr. 2011. http://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/pubmed/21634079.
27. VerPlank L, et al. Chemical genetic analysis of platelet granule secretion-probe 1. Probe Reports from NIH Mol Libr Program. 2011. http://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/pubmed/21634088.
28. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in G alpha(q)-deficient mice. Nature. 1997;389(6647):183-186.
29. Moers A, Nieswandt B, Massberg S, et al. G13 is an essential mediator of platelet activation in hemostasis and thrombosis. Nat Med. 2003;9(11):1418-1422.
30. th helix in signaling: the 7-8-1 receptor activation mechanism. J Biol Chem. 2006;281(7):4109-4116.
31. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J. 2003;373(Pt 1):65-70.
32. Riewald M, Ruf W. Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J Biol Chem. 2005;280(20):19808-19814.
33. Connolly AJ, Ishihara H, Kahn ML, Farese RV Jr, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature. 1996;381(6582):516-519.
34. Griffin CT, Srinivasan Y, Zheng YW, Huang W, Coughlin SR. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science. 2001;293(5535):1666-1670.
35. O'Donoghue ML, Bhatt DL, Wiviott SD, et al LANCELOT-ACS Investigators. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation. 2011;123(17):1843-1853.
36. Wiviott SD, Flather MD, O'Donoghue ML, et al LANCELOT-CAD Investigators. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial. Circulation. 2011;123(17):1854-1863.
37. Kosoglou T, Reyderman L, Tiessen RG, et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol. 2012;68(3):249-258.
38. Kosoglou T, Reyderman L, Kasserra C, et al. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol. 2012;68(3):291-300.
39. Katritch V, Cherezov V, Stevens RC. Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol Sci. 2012;33(1):17-27.
40. O'Callaghan K, Kuliopulos A, Covic L. Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem. 2012;287(16):12787-12796.
41. Covic L, Misra M, Badar J, Singh C, Kuliopulos A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med. 2002;8(10):1161-1165.
42. Nicholls DJ, Tomkinson NP, Wiley KE, et al. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol Pharmacol. 2008;74(5):1193-1202.
43. Salchow K, Bond ME, Evans SC, et al. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br J Pharmacol. 2010;159(7):1429-1439.
44. Andrews G, Jones C, Wreggett KA. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Mol Pharmacol. 2008;73(3):855-867.
45. McCoy KL, Gyoneva S, Vellano CP, Smrcka AV, Traynelis SF, Hepler JR. Protease-activated receptor 1 (PAR1) coupling to G(q/11) but not to G(i/o) or G(12/13) is mediated by discrete amino acids within the receptor second intracellular loop. Cell Signal. 2012;24(6):1351-1360.